Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report

Paxlovid has shown the potential decreasing the hospitalization rate of mild or moderate coronavirus disease 2019 (COVID-19) and death in few of clinical trials, and is expected to the most promising medicine targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SRAS-COV-2). However, there are...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Liulu, Zhang, Shasha, Han, Jing, Yi, Yile, Zhou, Hourong, Li, Jianquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
4400
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665888/
https://www.ncbi.nlm.nih.gov/pubmed/36397388
http://dx.doi.org/10.1097/MD.0000000000031361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665888/
https://www.ncbi.nlm.nih.gov/pubmed/36397388
http://dx.doi.org/10.1097/MD.0000000000031361

Ejemplares similares